Peter A. DeLong
Impact in
- Virology top 5%
- HIV Research and Treatment
- Biotechnology top 5%
- Cancer Research and Treatments
Papers in
- Oncology 6
- Cancer Immunotherapy and Biomarkers 2
- Cutaneous Melanoma Detection and Management 1
-
- Immune Cell Function and Interaction 3
- Co-authors
- Steven M Albelda (8 shared papers)Tomoyuki N. Tanaka (4 shared papers)Larry R. Kaiser (4 shared papers)Veena Kapoor (4 shared papers)Daniel H. Sterman (3 shared papers)Mamoru Watanabe (2 shared papers)Adam C. Henry (3 shared papers)Leslie A. Litzky (3 shared papers)
- Journals
- Cancer Biology & Therapy (3 papers)Clinical Cancer Research (2 papers)Molecular Therapy (1 paper)Journal of Virology (1 paper)Journal of Thoracic and Cardiovascular Surgery (1 paper)
- Partner nations
- United StatesLebanonIndia
In The Last Decade
Peter A. DeLong
20 papers receiving 779 citations
Peers
Comparison fields: 5 of 73
- Virology 98
- Biotechnology 106
- Immunology 198
- Oncology 224
- Pulmonary and Respiratory Medicine 239
Countries citing papers authored by Peter A. DeLong
This map shows the geographic impact of Peter A. DeLong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter A. DeLong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter A. DeLong more than expected).
Fields of papers citing papers by Peter A. DeLong
This network shows the impact of papers produced by Peter A. DeLong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter A. DeLong. The network helps show where Peter A. DeLong may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter A. DeLong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 107 | |
| 2 | 2005 | 103 | |
| 3 | Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. | 2003 | 80 |
| 4 | 1989 | 78 | |
| 5 | 2003 | 73 | |
| 6 | 2003 | 66 | |
| 7 | 1990 | 54 | |
| 8 | 2004 | 52 | |
| 9 | 2004 | 45 | |
| 10 | 2002 | 41 | |
| 11 | 2005 | 28 | |
| 12 | 2006 | 18 | |
| 13 | 2003 | 16 | |
| 14 | 2011 | 15 | |
| 15 | 1999 | 12 | |
| 16 | 2011 | 11 | |
| 17 | 2016 | 10 | |
| 18 | 2000 | 5 | |
| 19 | 2007 | 1 | |
| 20 | 2021 | 1 |
About Peter A. DeLong
Peter A. DeLong is a scholar working on Oncology, Immunology, Virology, Pulmonary and Respiratory Medicine and Pharmacology, having authored 20 papers that have together received 816 indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (3 papers), Immune Cell Function and Interaction (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), HIV Research and Treatment (2 papers), HIV/AIDS Research and Interventions (2 papers), Virus-based gene therapy research (2 papers), Cutaneous Melanoma Detection and Management (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Virology (98 citations), Biotechnology (106 citations), Immunology (198 citations), Oncology (224 citations) and Pulmonary and Respiratory Medicine (239 citations). Peter A. DeLong has collaborated with scholars based in United States, Lebanon and India. Frequent co-authors include Steven M Albelda, Tomoyuki N. Tanaka, Larry R. Kaiser, Veena Kapoor, Daniel H. Sterman, Mamoru Watanabe, Adam C. Henry, Larry R. Kaiser, Leslie A. Litzky and Robert J. Kruklitis. Their work appears in journals such as Cancer Biology & Therapy, Clinical Cancer Research, Molecular Therapy, Journal of Virology and Journal of Thoracic and Cardiovascular Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.